Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 14/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL298892 | 0.85 | NPC1 (0.38) | RORCALDH1A1LMNANPC1KDM4E | |
| Hydrochloric Acid SCHEMBL27854459 | 0.84 | RORC (0.36) | RORCALDH1A1LMNANPC1KDM4E | |
| SCHEMBL298837 | 0.83 | ALDH1A1 (0.44) | ALDH1A1LMNANPC1KDM4EL3MBTL1 | |
| SCHEMBL28056626 | 0.81 | ALDH1A1 (0.33) | ALDH1A1LMNANPC1KDM4EL3MBTL1 | |
| SCHEMBL24978140 | 0.78 | HTT (0.36) | RORCALDH1A1LMNAL3MBTL1HTT | |
| SCHEMBL16823687 | 0.78 | RORC (0.37) | RORC | |
| SCHEMBL25231234 | 0.76 | EPHX2 (0.37) | RORCALDH1A1LMNAKMT2ARAB9A | |
| SCHEMBL17942384 | 0.76 | KMT2A (0.38) | ALDH1A1L3MBTL1KMT2ASMN1; SMN2 | |
| SCHEMBL16825515 | 0.75 | RORC (0.35) | RORCALDH1A1LMNANPC1RAB9A | |
| SCHEMBL16825256 | 0.74 | TRPV4 (0.46) | RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10745364-B2 | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | LYCERA CORPORATION (US) | 2020-08-18 | — | — | US | disclosed |
| US-10442798-B2 | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2019-10-15 | — | — | US | disclosed |
| US-20190292159-A1 | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME LLC | 2019-09-26 | — | — | US | disclosed |
| US-10364237-B2 | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2019-07-30 | — | — | US | disclosed |
| US-10221146-B2 | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | LYCERA CORPORATION (US) | 2019-03-05 | — | — | US | disclosed |
| US-20180265502-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | LYCERA CORPORATION | 2018-09-20 | — | — | US | disclosed |
| US-20180208587-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | LYCERA CORPORATION | 2018-07-26 | — | — | US | disclosed |
| US-9896441-B2 | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2018-02-20 | — | — | US | disclosed |
| US-20180030005-A1 | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME LLC | 2018-02-01 | — | — | US | disclosed |
| US-9809561-B2 | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | MERCK SHARP & DOHME CORP. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9018228-B2 | Nematocidal sulfonamides | E I DU PONT DE NEMOURS AND COMPANY (US) | 2015-04-28 | — | — | US | disclosed |
| EP-2427058-B1 | NEMATOCIDAL SULFONAMIDES | DU PONT (US) | 2014-12-31 | — | — | EP | disclosed |
| US-20140221203-A1 | NEMATOCIDAL SULFONAMIDES | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-08-07 | — | — | US | disclosed |
| US-8735588-B2 | Nematocidal sulfonamides | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-05-27 | — | — | US | disclosed |
| US-20140088309-A1 | NEMATOCIDAL SULFONAMIDES | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-03-27 | — | — | US | disclosed |
| US-8623890-B2 | Nematocidal sulfonamides | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-01-07 | — | — | US | disclosed |
| US-20120114624-A1 | NEMATOCIDAL SULFONAMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-05-10 | — | — | US | disclosed |
| CN-102413693-A | Nematocidal sulfonamides | DU PONT | 2012-04-11 | — | — | CN | disclosed |
| EP-2427058-A2 | NEMATOCIDAL SULFONAMIDES | E. I. du Pont de Nemours and Company (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129500-A2 | NEMATOCIDAL SULFONAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030005-A1 | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | RORB, RORA, RORC | RORC 3/4885ALDH1A1 696/4885LMNA 3604/4885 |
| US-10745364-B2 | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | RORB, RORA, RORC | RORC 3/4885ALDH1A1 696/4885LMNA 3604/4885 |
| US-20180265502-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | RORA, RORB, RORC | RORC 3/4885ALDH1A1 602/4885LMNA 4270/4885 |
| US-10364237-B2 | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | RORA, RORC, RORB | RORC 2/4885ALDH1A1 762/4885LMNA 4447/4885 |
| US-20140221203-A1 | NEMATOCIDAL SULFONAMIDES | NSFL1C, QSOX1, Q6ZSR9 | RORC 3127/4885ALDH1A1 2283/4885LMNA 3730/4885 |
| US-20120114624-A1 | NEMATOCIDAL SULFONAMIDES | NSFL1C, QSOX1, Q6ZSR9 | RORC 3127/4885ALDH1A1 2283/4885LMNA 3730/4885 |
| US-20140088309-A1 | NEMATOCIDAL SULFONAMIDES | NSFL1C, QSOX1, Q6ZSR9 | RORC 3127/4885ALDH1A1 2283/4885LMNA 3730/4885 |
| US-20190292159-A1 | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | RORB, RORA, RORC | RORC 3/4885ALDH1A1 696/4885LMNA 3604/4885 |
| US-10442798-B2 | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | RORA, RORC, RORB | RORC 2/4885ALDH1A1 762/4885LMNA 4447/4885 |
| US-20180208587-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | RORA, RORB, RORC | RORC 3/4885ALDH1A1 602/4885LMNA 4270/4885 |
| US-10221146-B2 | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | RORB, RORA, RORC | RORC 3/4885ALDH1A1 722/4885LMNA 3553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.